Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 4,820,000 shares, a growth of 8.6% from the December 15th total of 4,440,000 shares. Approximately 19.6% of the shares of the company are sold short. Based on an average daily volume of 400,900 shares, the days-to-cover ratio is currently 12.0 days.

Arcturus Therapeutics Stock Down 1.3 %

Shares of Arcturus Therapeutics stock opened at $16.79 on Tuesday. The company has a market cap of $454.84 million, a PE ratio of -7.56 and a beta of 2.63. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The business has a 50 day moving average price of $17.38 and a 200-day moving average price of $19.80.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million during the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same period last year, the business posted ($0.61) earnings per share. As a group, research analysts anticipate that Arcturus Therapeutics will post -2.31 EPS for the current year.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $66.75.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Sumitomo Mitsui Trust Group Inc. raised its holdings in Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after acquiring an additional 712,650 shares during the period. ARK Investment Management LLC increased its stake in Arcturus Therapeutics by 6.9% in the 3rd quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock worth $48,765,000 after acquiring an additional 136,074 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Arcturus Therapeutics by 250.1% in the 2nd quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after acquiring an additional 396,505 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Arcturus Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after acquiring an additional 5,789 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Arcturus Therapeutics by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after acquiring an additional 3,224 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.